Worth reading
56In focus
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
680
億円（通期営業利益予想の増額）Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Interim period (second quarter)2025年1月1日〜2025年6月30日ConsolidatedIFRSNet Sales1,734,543¥ millionYear on year +10.5%Progress 51.9%
Operating profit479,871¥ millionYear on year +10.9%Progress 64.9%
Net income attributable to owners of the parent319,905¥ millionYear on year +4.8%Progress 64.8%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share180.19円
Financial position at period-end
Total assets8,262,786¥ million
of which net assets 4,141,838 ¥ millionEquity ratio 49.1%vs. prior year-end +4.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+167,451
Investment-131,965
Financials-230,877
Net change-195,391
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥865,185 million
Segment revenueTobacco business ¥1,608,779 million, Pharmaceuticals ¥48,331 million, Processed Food Operations ¥76,747 million
Segment profitたばこ事業（調整後営業利益） ¥556,142 million, 医薬事業（調整後営業利益） ¥4,163 million, 加工食品事業（調整後営業利益） ¥2,568 million
Regional sales¥417,314 million, ¥363,802 million, ¥771,425 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥3,344,000 million (YoY +6.2%)
Operating profit¥739,000 million (YoY +128.5%)
Ordinary incomeNot disclosed
Net income¥494,000 million (YoY +175.6%)
Revision to Earnings ForecastRevenue ¥32,730 100 million → ¥33,440 100 million（+2.2%） / Adjusted operating profit ¥7,350 100 million → ¥8,240 100 million（+12.1%） / Operating profit ¥6,710 100 million → ¥7,390 100 million（+10.1%） / Profit for the period (attributable to owners of the parent) ¥4,500 100 million → ¥4,940 100 million（+9.8%） / 為替一定ベース調整後営業利益 ¥8,150 100 million → ¥8,620 100 million（+5.8%）
Annual Dividend Forecast¥194 → ¥208（+7.2%）
Factors Behind Changes in Business Performance
業績予想については、足元までの状況等を織り込んだことに伴い修正したと説明している。中間期の業績全体については、詳細を決算説明会資料で説明するとしている。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not disclosed
Impairment loss¥25,183 million
Breakdown of extraordinary income (loss)調整項目（収益） リストラクチャリング収益 ¥7 million, Other ¥428 million / 調整項目（費用） Restructuring costs ¥25,413 million, Other ¥10 million
Depreciation and amortization¥97,452 million (depreciation and amortization)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for analysts and institutional investors)
Issued Shares at Period-End2,000,000,000 Shares
Treasury Shares at Period-End224,604,356 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年1月1日〜2025年6月30日 |
| Net Sales | ¥1,734,543 million (YoY +10.5%) |
| Operating profit | ¥479,871 million (YoY +10.9%) |
| Profit attributable to owners of the parent | ¥319,905 million (YoY +4.8%) |
| Net income per share | 180.19円 |
| Equity ratio | End of the current fiscal period 49.1 / End of previous period 45 |
| Total assets | ¥8,262,786 million |
| Net assets | ¥4,141,838 million |
| Cash flows from operating activities | ¥167,451 million |
| Cash flows from investing activities | ¥-131,965 million |
| Cash flows from financing activities | ¥-230,877 million |
| Cash and cash equivalents at end of period | ¥865,185 million |
| Full-year earnings forecast | Net Sales ¥3,344,000 million (YoY +6.2%) / Operating profit ¥739,000 million (YoY +128.5%) / Ordinary income Not disclosed / Net income ¥494,000 million (YoY +175.6%) |
| Revision to Earnings Forecast | Revenue ¥32,730 100 million → ¥33,440 100 million（+2.2%） / Adjusted operating profit ¥7,350 100 million → ¥8,240 100 million（+12.1%） / Operating profit ¥6,710 100 million → ¥7,390 100 million（+10.1%） / Profit for the period (attributable to owners of the parent) ¥4,500 100 million → ¥4,940 100 million（+9.8%） / 為替一定ベース調整後営業利益 ¥8,150 100 million → ¥8,620 100 million（+5.8%） |
| Annual Dividend Forecast | ¥194 → ¥208（+7.2%） |
| Segment revenue | Tobacco business ¥1,608,779 million, Pharmaceuticals ¥48,331 million, Processed Food Operations ¥76,747 million |
| Segment profit | たばこ事業（調整後営業利益） ¥556,142 million, 医薬事業（調整後営業利益） ¥4,163 million, 加工食品事業（調整後営業利益） ¥2,568 million |
| Regional sales | ¥417,314 million, ¥363,802 million, ¥771,425 million |
| Depreciation and amortization | ¥97,452 million (depreciation and amortization) |
| Impairment loss | ¥25,183 million |
| Breakdown of extraordinary income (loss) | 調整項目（収益） リストラクチャリング収益 ¥7 million, Other ¥428 million / 調整項目（費用） Restructuring costs ¥25,413 million, Other ¥10 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 2,000,000,000 Shares |
| Treasury Shares at Period-End | 224,604,356 Shares |
| Factors Behind Changes in Business Performance | 業績予想については、足元までの状況等を織り込んだことに伴い修正したと説明している。中間期の業績全体については、詳細を決算説明会資料で説明するとしている。 |
Items this document does not state (6)
Ordinary incomeOperating MarginPayout ratioShareholder Return PolicyOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、足元までの状況等を織り込んだことに伴い業績予想を修正したとしている。配当予想の修正について、具体的な理由は記載していない。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.